Clinical Trial: A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

U.S., April 22 -- ClinicalTrials.gov registry received information related to the study (NCT07543380) titled 'A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.' on April 15.

Brief Summary: The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.

The study is seeking participants who are:

* 18 to 59 years of age

* adults with health condition(s) that can put them at an increased risk of severe RSV disease

It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the resea...